Christoffer Lorenzen appointed CEO of Karo Pharma; Peter Blom resigning.
The Board of Karo Pharma Aktiebolag (publ) (“Karo Pharma”) has appointed Christoffer Lorenzen as the new CEO of Karo Pharma, replacing Peter Blom. Christoffer will take on his new position on July 1, 2019. Up until this date, and effective as of today, Ulf Mattsson assumes the CEO position on an interim basis. Karo Pharma has grown rapidly in recent years fueled by the acquisitions of BioPhausia in 2016, Weifa in 2017 and a product portfolio from Leo Pharma in 2018. In January 2019, EQT, one of the largest private equity investors in Europe, through Karo Intressenter AB, acquired a